You just read:

FDA Approves Bayer's New Class of Drug Adempas® (riociguat) tablets to Treat Adults with PAH and Persistent, Recurrent or Inoperable CTEPH

News provided by

Bayer HealthCare Pharmaceuticals

08 Oct, 2013, 18:54 ET